Subcortical surface morphometry in substance dependence: An ENIGMA addiction working group study
Chye, Yann; Mackey, Scott; Gutman, Boris A.; Ching, Christopher R.K.; Batalla, Albert; Blaine, Sara; Brooks, Samantha; Caparelli, Elisabeth C.; Cousijn, Janna; Dagher, Alain; Foxe, John J.; Goudriaan, Anna E.; Hester, Robert; Hutchison, Kent; Jahanshad, Neda; Kaag, Anne M.; Korucuoglu, Ozlem; Li, Chiang Shan R.; London, Edythe D.; Lorenzetti, Valentina; Luijten, Maartje; Martin-Santos, Rocio; Meda, Shashwath A.; Momenan, Reza; Morales, Angelica; Orr, Catherine; Paulus, Martin P.; Pearlson, Godfrey; Reneman, Liesbeth; Schmaal, Lianne; Sinha, Rajita; Solowij, Nadia; Stein, Dan J.; Stein, Elliot A.; Tang, Deborah; Uhlmann, Anne; van Holst, Ruth; Veltman, Dick J.; Verdejo-Garcia, Antonio; Wiers, Reinout W.; Yücel, Murat; Thompson, Paul M.; Conrod, Patricia; Garavan, Hugh
(2020) Addiction Biology, volume 25, issue 6, pp. 1 - 15
(Article)
Abstract
While imaging studies have demonstrated volumetric differences in subcortical structures associated with dependence on various abused substances, findings to date have not been wholly consistent. Moreover, most studies have not compared brain morphology across those dependent on different substances of abuse to identify substance-specific and substance-general dependence effects. By pooling
... read more
large multinational datasets from 33 imaging sites, this study examined subcortical surface morphology in 1628 nondependent controls and 2277 individuals with dependence on alcohol, nicotine, cocaine, methamphetamine, and/or cannabis. Subcortical structures were defined by FreeSurfer segmentation and converted to a mesh surface to extract two vertex-level metrics—the radial distance (RD) of the structure surface from a medial curve and the log of the Jacobian determinant (JD)—that, respectively, describe local thickness and surface area dilation/contraction. Mega-analyses were performed on measures of RD and JD to test for the main effect of substance dependence, controlling for age, sex, intracranial volume, and imaging site. Widespread differences between dependent users and nondependent controls were found across subcortical structures, driven primarily by users dependent on alcohol. Alcohol dependence was associated with localized lower RD and JD across most structures, with the strongest effects in the hippocampus, thalamus, putamen, and amygdala. Meanwhile, nicotine use was associated with greater RD and JD relative to nonsmokers in multiple regions, with the strongest effects in the bilateral hippocampus and right nucleus accumbens. By demonstrating subcortical morphological differences unique to alcohol and nicotine use, rather than dependence across all substances, results suggest substance-specific relationships with subcortical brain structures.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: addiction, structural MRI, substance dependence, Psychiatry and Mental health, Medicine (miscellaneous), Pharmacology, Journal Article
ISSN: 1355-6215
Publisher: Wiley-Blackwell
Note: Funding Information: This work was supported in part by National Institutes of Health (NIH) grant U54EB020403 from the Big Data to Knowledge (BD2K) program. Dr Y. Chye was supported by the Monash Bridging Post doctoral Fellowship. Data collection: Dr C.R.K. Ching was supported by National Institutes of Health grants NIA T32AG058507, NIH/NIMH 5T32MH073526, and U54EB020403. Dr J. Cousijn and Dr A.E. Goudriaan received funding for the Cannabis Prospective Study from Netherlands Organization for Health Research and Development (ZonMW) grant 31180002 from Netherlands Organization for Scientific Research (NWO). Dr A. Dagher received support from the Canadian Institutes for Health Research (CIHR) Foundation Scheme. Dr H. Garavan and Dr J.J. Foxe received funding from the National Institute on Drug Abuse (NIDA) grant R01‐DA014100. Dr A.E. Goudriaan and Dr R.J. van Holst received funding from ZonMW grant 91676084 from NWO. Dr. A. E. Goudriaan is supported by an NWO‐ZonMw VIDI grant 91713354. Dr O. Korucuoglu received support for the neuro‐ADAPT study from the VICI grant 453.08.001 from the NWO, awarded to Dr R.W. Wiers. Dr C.R. Li received funding from NIDA grants R01AA021449, R01DA023248, and K25DA040032. Dr E.D. London received support from NIH grants DA15179, DA022539, and DA024853, F30 DA021961 (KB), and MOI‐RR‐00865 (UCLA GCRC); endowments from the Katherine K. and Thomas P. Pike Chair in Addiction Studies and Marjorie M. Greene Trust, Philip Morris USA UCLA contract 20063287, and institutional training grants T32 DA 024635 (support of Angelica Morales) and T32 MH17140 (support of Golnaz Tabibnia). Dr M. Luitjen and Dr D.J. Veltman received support from the VIDI grant 016.08.322 from NWO, awarded to Ingmar H.A. Franken. Dr R. Momenan received support from the National Institutes of Alcohol Abuse and Alcoholism (NIAAA)/NIH intramural research funding ZIA AA000125–04 to the Clinical NeuroImaging Research Core. Dr A. Morales received support from NIDA grant T32 DA024635. Dr M.P. Paulus received funding from National Institute of Mental Health (NIMH) grant R01 DA018307. Dr G. Pearlson received funding from the NIDA grant R01 DA020709 and the NIAAA grants AA016599 and AA19036. Dr R. Martin‐Santos received support from Plan Nacional sobre Drogas. Ministerio de Sanidad y Política Social grant PNSD:2011/050 and SGR:2014/1114. Dr L. Reneman received funding from the Netherlands Organisation for Health Research and Development 40‐00812‐98‐11002. Dr L. Schmaal and Dr D.J. Veltman received funding from ZonMW grant 31160003 from NWO. Dr R. Sinha received funding from NIDA (PL31‐1DA024859‐01), NIH National Center for Research Resources (UL1‐RR24925‐01), and NIAAA grant (R01‐AA013892). Dr Z. Sjoerds and Dr D.J. Veltman received funding from ZonMW grant 31160004 from NWO. Dr N. Solowij received support from the Clive and Vera Ramaciotti Foundation for Biomedical Research, the National Health and Medical Research Council Project grant 459111, and Australian Research Council Future Fellowship grant FT110100752. Dr D. Stein received support from the South African Medical Research Council. Dr E.A. Stein received support from the Intramural Research Program of the National Institute on Drug Abuse (NIDA‐NIH). Dr. A. Verdejo‐Garcia received support from the Australian Medical Research Future Fund (MRF1141214). Dr M. Yücel received support from the National Health and Medical Research Council Fellowship grant 1117188 and the David Winston Turner Endowment Fund. Funding Information: The authors report no competing interest. Dr C.R.K. Ching and Dr P.M. Thompson receives partial research support from Biogen, Inc. (Boston) for research unrelated to the topic of this manuscript. Dr M. Yücel has received funding from Monash University and Australian Government funding bodies such as the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC), and the Department of Industry, Innovation and Science. He has also received philanthropic donations from the David Winston Turner Endowment Fund as well as payment from law firms in relation to court and/or expert witness reports. Publisher Copyright: © 2019 Society for the Study of Addiction Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
(Peer reviewed)